BARCELONA, Spain I December 12, 2024 I SpliceBio, a genetic medicines company pioneering Protein Splicing to address diseases caused by mutations in large genes, today announced that the U.S. Food & ...

— Following recently signed global license agreement with Synaffix, EO-1022 leverages the company’s GlycoConnect® and HydraSpace® ADC technologies for glycan site-specific conjugation and SYNstatin E™ ...

SEONGNAM, South Korea I 12, 2024 I SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention ...

NORTH CHICAGO, IL and MADISON, WI, USA I 13, 2024 I AbbVie (NYSE: ABBV) and Nimble Therapeutics today announced a definitive agreement under which ...

UNLOXCYT is the first and only FDA-approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma ...

REDWOOD CITY, CA, USA I December 11, 2024 I Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and ...

ZUG, Switzerland I 13, 2024 I Galderma (SWX:GALD) today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved ...

BOSTON, MA, USA I 11, 2024 I Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced ...

Interim data from Phase 1/2a study demonstrate near complete inhibition in hemolytic activity and functional activity of alternative complement pathway ...

WILMINGTON, DE, USA I 11, 2024 I Updated results from the OlympiA Phase III trial showed AstraZeneca and Merck & Co., Inc’s, known as MSD outside of the US and Canada, LYNPARZA ® (olaparib) ...

TOKYO, USA & NOVI, MI, USA & DÜSSELDORF, Germany I 11, 2024 I Asahi Kasei Pharma has taken another step in its transformation into a global ...

ATLANTA, GA, USA I December 11, 2024 I Expression Therapeutics, Inc., has presented the results of a Phase 1 clinical trial for its novel lentiviral ...